Oncolytic viruses have a…complicated history.

Imlygic got approved in 2015 for melanoma and immediately became the modality that almost nobody talks about at conferences.

The concept was always elegant: program a virus to kill tumor cells, program them to express and release cytokines in the process, the dying cells release cytokines and tumor antigens, the immune system finally sees the tumor it’s been ignoring.

The reality has been intratumoral injections that don’t scale, replication that doesn’t reach metastases, and efficacy that disappoints.

Theolytics, an Oxford spin-out, thinks the field has been solving the wrong problem. Their theory is that the tumor microenvironment, especially in stroma-heavy cancers like ovarian, is what’s been killing oncolytic therapy.

So they built a virus that kills both the tumor and the stroma.

This week, Theolytics dosed the first patient in OCTOPOD-IP, a U.S. Phase 1 trial of THEO-260 in platinum-resistant ovarian cancer, run in collaboration with MD Anderson.

The trial uses intraperitoneal delivery directly into the abdominal cavity where ovarian tumors live and spread.

This sits alongside their parallel international OCTOPOD trial (NCT06618235), enrolling roughly 28 patients across the UK, Spain, and Canada with intravenous THEO-260.

Two delivery routes, same drug, complementary datasets.

Pretty smart trial design.

But its the drug itself that I find most interesting…obviously!

THEO-260 is an oncolytic adenovirus selected from a phenotypic screen of over 100 million candidates against ovarian tumors that include human cancer-associated fibroblasts.

Most oncolytic platforms screen against tumor cells in isolation.

Theolytics screened against the messy reality, and the candidate that won was one that lyses both the tumor cell population AND the CAFs that drive chemoresistance, T-cell exclusion, and relapse.

In preclinical models with human CAFs included in the system, THEO-260 wiped out tumor volume completely.

We’ve cured cancer in mice a million times. Whether that translates to humans is the entire question of the next eighteen months.

The capital story is solid.

£19 million Series B in April 2024 from M Ventures, Taiho Ventures, Epidarex, Sound Bioventures, Oxford Science Enterprises, and BGF.

Another £2 million from Innovate UK in September 2024 for biomarker work.

Then €8 million in non-dilutive Horizon Europe grant funding earlier this year.

Cumulative haul is around $53 million, with most of it going into clinical execution rather than overhead.

Platinum-resistant ovarian cancer is a brutal indication.

Five-year survival is grim, treatment options are minimal after the first relapse, and CAF biology is a known driver of treatment failure.

If THEO-260’s dual mechanism shows even modest objective response in OCTOPOD-IP or OCTOPOD-IV, the conversation about oncolytic viruses changes.

And if it doesn’t, the field keeps waiting for someone to make the modality work.